GlobeNewswire by notified

Orion Corporation: Managers’ transactions – Satu Ahomäki

27.2.2023 12:30:00 CET | GlobeNewswire by notified

Share

ORION CORPORATION
MANAGERS’ TRANSACTIONS
27 FEBRUARY 2023 at 13.30 EET

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Satu Ahomäki
Position: Other senior manager

Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 26098/7/6

____________________________________________

Transaction date: 2023-02-24
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL

Transaction details
(1): Volume: 4 Unit price: 46.5 EUR
(2): Volume: 7 Unit price: 46.5 EUR
(3): Volume: 19 Unit price: 46.5 EUR
(4): Volume: 22 Unit price: 46.5 EUR
(5): Volume: 30 Unit price: 46.5 EUR
(6): Volume: 36 Unit price: 46.5 EUR
(7): Volume: 56 Unit price: 46.5 EUR
(8): Volume: 104 Unit price: 46.5 EUR
(9): Volume: 123 Unit price: 46.5 EUR
(10): Volume: 125 Unit price: 46.5 EUR
(11): Volume: 125 Unit price: 46.5 EUR
(12): Volume: 261 Unit price: 46.5 EUR
(13): Volume: 340 Unit price: 46.5 EUR
(14): Volume: 688 Unit price: 46.5 EUR
(15): Volume: 815 Unit price: 46.5 EUR
(16): Volume: 842 Unit price: 46.5 EUR
(17): Volume: 1403 Unit price: 46.5 EUR

Aggregated transactions (17):
Volume: 5000 Volume weighted average price: 46.5 EUR

Orion Corporation

Liisa Hurme

President and CEO		Olli Huotari

SVP, Corporate Functions

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast27.3.2023 15:05:00 CEST | Press release

OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference C

Transactions in connection with share buy-back program27.3.2023 15:00:41 CEST | Press release

Company Announcement COPENHAGEN, Denmark; March 27, 2023 –Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 31, 2023, and comprises up to 220,000 shares. The following transactions were executed under the program from March 20, 2023, to March 24, 2023: No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement167,000427,631,620March 20, 20236,0002,504.2415,025,440March 21, 20235,000 2,541.7712,708,850March 22,20235,0002,541.4412,707,200March 23, 20237,0002,529.9917,709,930March 24, 20237,0002,564.9117,954,370Total30,00076,105,790Accumulated under the program197,000503,737,410 Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 740,416 shares as treasury shares, corresponding to 1.12% of the to

Philips Virtual Care Management offers a comprehensive approach to telehealth for patients, providers and payers27.3.2023 15:00:00 CEST | Press release

March 27, 2023 New solution demonstrates proven results in improving patient engagement, health outcomes, and lowering cost of care while enabling workflow efficiencies Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the debut of Philips Virtual Care Management, a comprehensive portfolio of flexible solutions and services to help health systems, providers, payers and employer groups more meaningfully motivate and deeply connect with patients from virtually anywhere. Philips Virtual Care Management can help reduce pressure on hospital staff by decreasing emergency department visits, as well as reducing the cost of care through better management of chronic disease [1][2]. Every year, chronic condition management represents 90% of healthcare expenditures in the USA [3]. Philips Virtual Care Management’s condition-specific protocols now include diabetes, hypertension, heart disease, chronic kidney disease, chronic obst